A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
about
Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionProgress in systemic therapy of advanced hepatocellular carcinomaHepatocellular carcinoma: Will novel targeted drugs really impact the next future?Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?CIViC databaseAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaCombination treatment including targeted therapy for advanced hepatocellular carcinomaEvolving role of Sorafenib in the management of hepatocellular carcinoma.Systemic treatment of hepatocellular carcinoma: Past, present and futureOvercoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Novel drugs in clinical development for hepatocellular carcinoma.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Chemotherapy for hepatocellular carcinoma: The present and the future.Ongoing challenges in the diagnosis of hepatocellular carcinoma.Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.Circulating Tumor DNA Testing for Liver Cancer.Molecular classification of hepatocellular carcinoma: potential therapeutic implications.Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Current Development Status of MEK Inhibitors.Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study.Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.Determination of Structural Requirements of N-Substituted Tetrahydro-β-Carboline Imidazolium Salt Derivatives Using in Silico Approaches for Designing MEK-1 Inhibitors.Hepatocellular carcinoma
P2860
Q26738860-D249E4A3-39A8-47D5-B539-DC4378651810Q26740217-139AAE6D-A65C-41D6-A680-07088FB07AD0Q26741201-7BE93782-4AC4-456D-A008-EE08EA3A6712Q26766689-A78630BD-5B12-4FB3-BBF0-E66D81E621ECQ27612411-F03FB714-B789-45ED-ABA3-37597E5D6D78Q28075305-0B1DCEB6-98E3-4011-99F7-313CA4FAC5A0Q28077738-5EE71651-017C-4762-AE2E-424FFEC0FC49Q33779864-2D89F890-3BCF-4036-83E9-4806F2B76951Q33854034-81057C1E-C395-4D3E-B88A-849F049BC246Q37690136-191F142B-70AB-41D1-99DB-05D6EE8F9EEFQ38387061-07474197-E5FF-4CEE-84F0-F12B1DDECB27Q38444096-8E58798C-8C2B-43F9-8827-70A2A43F57F8Q38521011-97D11B93-7F3A-4CCD-8ED9-6E8FE61C6426Q38537138-870320B0-4898-4E5E-93D9-349BFD2112FFQ38554422-73DAFED8-DE22-4664-A0B7-713F2F749BECQ38635603-50BD5F8C-822A-4591-A4FA-73F300E2A232Q38639762-D41538D4-E6D4-4777-BDEC-20BCC5A7EBE2Q38646886-43B412E1-C6BF-4024-8267-439BB1DFA379Q39307416-836D1355-C29A-422E-A440-26D86B88C065Q39366121-13B25641-E11A-44FA-B5F7-835D468E8206Q42322534-C53035A8-F3ED-4EE4-ADF0-BB88F7F1215DQ43059019-7B42FE96-DD45-490A-B28C-0D772CCBEAC1Q47134647-61D78B88-448D-44C2-A34A-F8B15DEB5E4DQ47735535-6493186C-A321-40D9-894C-89E035E617FEQ49739733-1C98EB7D-DA05-45B3-A42F-0F9AC66ECC08Q49788208-496D10FA-9FF8-4F50-8225-8B17B48040B5Q50936315-BB5AAA15-F51A-4C14-A9C3-BA0B5F481745Q57756376-040F4313-0B03-4D77-B616-931F3ECD5C1F
P2860
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A phase II study of the effica ...... able hepatocellular carcinoma.
@ast
A phase II study of the effica ...... able hepatocellular carcinoma.
@en
A phase II study of the effica ...... able hepatocellular carcinoma.
@nl
type
label
A phase II study of the effica ...... able hepatocellular carcinoma.
@ast
A phase II study of the effica ...... able hepatocellular carcinoma.
@en
A phase II study of the effica ...... able hepatocellular carcinoma.
@nl
prefLabel
A phase II study of the effica ...... able hepatocellular carcinoma.
@ast
A phase II study of the effica ...... able hepatocellular carcinoma.
@en
A phase II study of the effica ...... able hepatocellular carcinoma.
@nl
P2093
P50
P3181
P1476
A phase II study of the effica ...... table hepatocellular carcinoma
@en
P2093
Cheng-Yao Lin
Chia-Jui Yen
Christian Kappeler
Heiko Krissel
Ho Yeong Lim
Joong-Won Park
Kun-Ming Rau
Miah Hiang Tay
P304
P3181
P356
10.1158/1078-0432.CCR-13-3445
P407
P577
2014-10-07T00:00:00Z